His main research concerns Internal medicine, Colorectal cancer, Surgery, Capecitabine and Fluorouracil. His Internal medicine research integrates issues from Gastroenterology and Oncology. His Oncology research is multidisciplinary, incorporating elements of Clinical endpoint, Ovarian cancer, FOLFOX and Hazard ratio.
His research in Colorectal cancer is mostly focused on Oxaliplatin. Jim Cassidy has included themes like Odds ratio and Clinical trial in his Surgery study. In his study, Metabolite is strongly linked to Pharmacokinetics, which falls under the umbrella field of Chemotherapy.
His scientific interests lie mostly in Internal medicine, Colorectal cancer, Oncology, Chemotherapy and Cancer. His Internal medicine research incorporates themes from Gastroenterology and Surgery. His Colorectal cancer research includes elements of Bevacizumab, Bolus, Survival rate and Hazard ratio.
He focuses mostly in the field of Oncology, narrowing it down to topics relating to Randomized controlled trial and, in certain cases, Physical therapy and Cyclophosphamide. Jim Cassidy combines subjects such as Pharmacokinetics, Pharmacology and Endocrinology with his study of Chemotherapy. His studies in Cancer integrate themes in fields like Cancer research and Pathology.
Internal medicine, Oncology, Colorectal cancer, Cancer and Chemotherapy are his primary areas of study. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery. His Oncology research includes themes of KRAS, Cetuximab, Irinotecan and First line treatment.
His Colorectal cancer research is multidisciplinary, incorporating perspectives in Adjuvant, Fluorouracil and Hazard ratio. When carried out as part of a general Cancer research project, his work on Metastasis is frequently linked to work in Biomarker discovery, therefore connecting diverse disciplines of study. The Chemotherapy study combines topics in areas such as Radiation therapy, Radiology, Gastrointestinal cancer and Extravasation.
Jim Cassidy mostly deals with Internal medicine, Oncology, Colorectal cancer, Surgery and Oxaliplatin. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His study in Oncology is interdisciplinary in nature, drawing from both Adjuvant therapy, KRAS, Cetuximab and Irinotecan.
Jim Cassidy has researched Colorectal cancer in several fields, including Fluorouracil and Hazard ratio. He studies Bevacizumab, a branch of Surgery. His Oxaliplatin research incorporates elements of Regimen and Advanced colorectal cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Leonard B. Saltz;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer.
Journal of Clinical Oncology (2008)
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt.
The New England Journal of Medicine (2005)
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study
Eric Van Cutsem;Chris Twelves;Jim Cassidy;David Allman.
Journal of Clinical Oncology (2001)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero.
Journal of Clinical Oncology (2010)
Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy.
Journal of the National Cancer Institute (2000)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
Paul A. Vasey;Stan B. Kaye;Rosemary Morrison;Chris Twelves.
Clinical Cancer Research (1999)
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Jim Cassidy;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer.
Journal of Clinical Oncology (2008)
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Johannes Schüller;Jim Cassidy;Etienne Dumont;Brigitte Roos.
Cancer Chemotherapy and Pharmacology (2000)
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
Jim Cassidy;Josep Tabernero;Chris Twelves;René Brunet.
Journal of Clinical Oncology (2004)
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J. Cassidy;C. Twelves;E. Van Cutsem;P. Hoff.
Annals of Oncology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: